Definium Therapeutics (DFTX) Stock Soars 52% on Breakthrough Depression Trial Results - Blockonomi
Definium Therapeutics (DFTX) stock rocketed 52% after Phase 3 Emerge trial showed DT120 significantly improved depression scores with clean safety profile.
22 Jun 14:36 · Blockonomi